Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Zacks Investment Research issued their Q2 2021 earnings estimates for Tonix Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 7th. Zacks Investment Research analyst D. Bautz expects that the company will earn ($0.05) per share for the quarter. Zacks Investment Research also issued estimates for Tonix Pharmaceuticals’ FY2023 earnings at ($0.16) EPS.
Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Sunday, March 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02).
NASDAQ:TNXP opened at $1.16 on Thursday. The business’s 50-day moving average price is $1.27 and its 200 day moving average price is $0.92. Tonix Pharmaceuticals has a 52-week low of $0.51 and a 52-week high of $2.46. The firm has a market cap of $375.74 million, a P/E ratio of -0.33 and a beta of 1.57.
Several hedge funds and other institutional investors have recently bought and sold shares of TNXP. BlackRock Inc. boosted its stake in shares of Tonix Pharmaceuticals by 2,776,605.7% during the 3rd quarter. BlackRock Inc. now owns 1,471,654 shares of the company’s stock worth $1,236,000 after acquiring an additional 1,471,601 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Tonix Pharmaceuticals by 1,344.3% in the 4th quarter. GSA Capital Partners LLP now owns 1,141,049 shares of the company’s stock valued at $770,000 after purchasing an additional 1,062,048 shares during the period. Squarepoint Ops LLC increased its stake in Tonix Pharmaceuticals by 118.1% in the 4th quarter. Squarepoint Ops LLC now owns 680,083 shares of the company’s stock worth $459,000 after purchasing an additional 368,216 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Tonix Pharmaceuticals in the 4th quarter worth about $183,000. Finally, Northern Trust Corp raised its holdings in Tonix Pharmaceuticals by 4.8% during the 4th quarter. Northern Trust Corp now owns 262,985 shares of the company’s stock worth $178,000 after buying an additional 12,127 shares during the period. 2.23% of the stock is currently owned by institutional investors.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, manufacturing, and licensing small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions.
Featured Story: Portfolio Manager
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.